Cite
91P Preexisting tumor host immunity delineates clinical outcomes in resectable non-small cell lung cancer
MLA
P. Rocha, et al. “91P Preexisting Tumor Host Immunity Delineates Clinical Outcomes in Resectable Non-Small Cell Lung Cancer.” Annals of Oncology, vol. 33, Apr. 2022, p. S75. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........7725621331cad9968e7a093a4336736f&authtype=sso&custid=ns315887.
APA
P. Rocha, M. Rodrigo, L. Moliner, A. Ríos-Hoyo, L. Masfarré, N. Navarro-Gorro, S. Menendez, A. Taus, A. Rodríguez, R. Aguiló, J. Belda, R. Del Rey-Vergara, M. Galindo, L. Comerma, & E. Arriola. (2022). 91P Preexisting tumor host immunity delineates clinical outcomes in resectable non-small cell lung cancer. Annals of Oncology, 33, S75.
Chicago
P. Rocha, M. Rodrigo, L. Moliner, A. Ríos-Hoyo, L. Masfarré, N. Navarro-Gorro, S. Menendez, et al. 2022. “91P Preexisting Tumor Host Immunity Delineates Clinical Outcomes in Resectable Non-Small Cell Lung Cancer.” Annals of Oncology 33 (April): S75. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........7725621331cad9968e7a093a4336736f&authtype=sso&custid=ns315887.